Ohr Pharmaceutical, Inc. S-3

   

Exhibit 12.1

 

STATEMENT REGARDING COMPUTATION OF RATIOS

 

 

   Year Ended September 30,  Nine Months Ended
June 30,
   2012  2013  2014  2015  2016  2017
         (in thousands)         
Computation of Earnings:                  
Pretax loss  $(1,454,884.00)  $(5,652,488.00)  $(9,130,664.00)  $(15,197,865.00)  $(25,766,198.00)  $(18,566,555.00)
Adjustments to earnings:                              
Fixed charges (as computed below)  $1,817.02   $4,689.38   $33,149.92   $113,101.18   $118,813.61   $85,447.19 
Earnings as adjusted  $(1,453,066.98)  $(5,647,798.62)  $(9,097,514.08)  $(15,084,763.82)  $(25,647,384.39)  $(18,481,107.82)
                               
Computation of Fixed Charges:                              
Capitalized interest  $1,817.02   $4,689.38   $5,576.32   $5,977.52   $6,592.58   $6,274.74 
Estimated interest component of rent expense            $27,573.60   $107,123.66   $112,221.03   $79,172.45 
Total fixed charges  $1,817.02   $4,689.38   $33,149.92   $113,101.18   $118,813.61   $85,447.19 
Deficiency of earnings available to cover    1,454,884.00 (a)    5,652,488.00 (a)    9,130,664.00 (a)    15,197,865.00 (a)    25,766,198.00 (a)    18,566,550.01 (a)

 

 (a) Earnings were inadequate to cover combined fixed charges for the periods presented.